Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Shrivel, but Many Beat Conservative Guidance
June 11, 2019
- Amicus to Enroll PIII Study for Pompe Therapy AT-GAA by Year-End: COO
June 10, 2019
- Napabucasin PIII Colorectal Cancer Trial to Continue: Sumitomo Dainippon
June 10, 2019
- Keytruda Tops Drug Sales Ranking in May: Encise Snapshot
June 10, 2019
- Pfizer Keeps Diverse Portfolio Strategy amid Sluggish Bavencio, Oncology Chief Says I/O Just One Area of Cancer Care
June 10, 2019
- Oral MDS Treatment ASTX727 Equivalent to IV Dacogen in PIII Study: Otsuka
June 10, 2019
- Taiho to Commercialize Otsuka US Subsidiary’s 2 Cancer Drugs in North America
June 10, 2019
- Konica Minolta Joins Hands with Univ. of Tokyo, NCC on Genetic Profiling
June 7, 2019
- Royalties Push Up Profits at 3 Major Makers, Shionogi Sees 40% Operating Margin This Year
June 7, 2019
- Boehringer’s Japan Pharma Sales on Course for Recovery; Jardiance, Spiolto Upbeat
June 7, 2019
- Astellas Ties Up with Microsoft to Develop Tool Using “Mixed Reality” to Improve Medication Adherence
June 7, 2019
- Fujifilm Toyama Chemical’s T-817MA Enters PII to Examine Post-Stroke Rehabilitation Enhancement Effects
June 7, 2019
- Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019
- Merck SVP Roy Baynes Recounts Keytruda Development, Says We Followed Science
June 6, 2019
- Japan Fair Trade Watchdog Issues Cease and Desist and Surcharge Payment Orders to Koa Isei for Price Fixing
June 6, 2019
- Otsuka Chemical Acquires Cefixime-Related Business from Astellas
June 6, 2019
- Fujifilm Develops Continuous Production System for Biologics, Set to Begin Contract Manufacturing in 2020
June 6, 2019
- Fujifilm Invests 200 Million Yen in Cell Therapy Startup
June 5, 2019
- Xofluza Hits Goal of Preventing Flu Onset in Japan PIII: Shionogi
June 5, 2019
- Astellas’s ADC Enfortumab Vedotin Logs 44% ORR in Advanced Urothelial Cancer in PII
June 5, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…